Ucb

UCB, a pharmaceutical preparation manufacturing company headquartered in Belgium, has outlined significant carbon emission reduction targets. In 2025, UCB reported total emissions of approximately 868.03 million kg CO2e, with Scope 1 emissions accounting for about 22.19 million kg CO2e, Scope 2 emissions at approximately 15,000 kg CO2e (market-based), and Scope 3 emissions reaching roughly 849.80 million kg CO2e. In 2024, total emissions were approximately 790.86 million kg CO2e, comprising Scope 1 of about 21.72 million kg CO2e, Scope 2 of approximately 5,000 kg CO2e (market-based), and Scope 3 of around 769.14 million kg CO2e. The company is committed to ambitious climate goals, including reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 73% by 2030, using 2019 as a base year. Additionally, UCB aims to achieve 100% renewable electricity by 2030.

UCB has also set a near-term target to reduce absolute Scope 3 GHG emissions by 48% by 2030 from a 2019 base year, covering specific categories such as fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products. Looking further ahead, UCB has a long-term commitment to reach net-zero greenhouse gas emissions across its value chain by 2045.

Further demonstrating its dedication to sustainability, UCB has committed to reducing its Scope 1, 2, and 3 GHG emissions by 38% by 2030, with 2015 as the base year. This commitment is recognised by the Science Based Targets initiative (SBTi). The company is also working to ensure that 80% of its suppliers, by emissions, will have science-based targets by 2028.